Abstract 305P
Background
The prognosis in patients with breast cancer with isolated locoregional recurrence (ILRR) without simultaneous distant metastases after immediate breast reconstruction (IBR) remains unknown. We aimed to investigate the prognosis in this patient population.
Methods
This multi-institutional retrospective observational study evaluated 3,295 patients with primary breast cancer who underwent IBR at 12 Japanese medical facilities between January 1, 2008 and December 31, 2016. The outcome measures were the prognostic factors for ILRR after IBR, 5-year distant metastasis-free survival (DMFS), and 5-year overall survival (OS).
Results
Mastectomy or skin-sparing mastectomy was performed in 3,295 patients. ILRR occurred in 70 patients, and the median observation period from ILRR diagnosis was 39.3 months. Of the 70 patients, 9 (12.9%) had axillary lymph node recurrence (ALNR) at the time of ILRR diagnosis. The 5-year DMFS after ILRR was 92.4%. Patients with ILRR who had ALNR had a significantly worse DMFS than that had by those without ALNR (P = 0.005).The 5-year OS after ILRR was 91.2%. Patients with ILRR who had ALNR had a significantly worse OS than that had by those without ALNR (P = 0.005).The relationship between DMFS and clinicopathological factors was analyzed using the Cox proportional hazards model. Univariate analysis revealed significant associations of pN at primary surgery (P = 0.041) and ALNR at ILRR (HR: 9.960, 95% CI: 1.400–70.862, P = 0.022) with DMFS. However, ALNR was the only independent prognostic factor for DMFS in the multivariate analysis (P = 0.041). Univariate analysis revealed significant associations of post-mastectomy radiation therapy (PMRT) at primary surgery (P = 0.023) and ALNR at ILRR (P = 0.043) with OS. In multivariate analysis, both PMRT (P = 0.010) and ALNR (P = 0.028) were independent prognostic factors for OS.
Conclusions
Although patients with breast cancer who have ILRR after IBR have a favorable prognosis overall, ALNR at the diagnosis of ILRR may be a poor prognostic factor. Our results may contribute to developing strategies to predict prognosis in patients with breast cancer who develop ILRR after IBR.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Collaborative Study Group of Scientific Research of the Japanese Breast Cancer Society.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
364P - Elacestrant in combination with abemaciclib in patients (pts) with brain metastasis (mets) from estrogen receptor-positive (ER+), HER2-negative (HER2-) breast cancer: Preliminary data from ELECTRA, an open-label, multicenter, phase Ib/II study
Presenter: Eva Ciruelos
Session: Poster session 14
365P - Interim analysis (IA) of the giredestrant (G) + samuraciclib (SAMURA) arm in MORPHEUS breast cancer (BC): A phase I/II study of G treatment (tx) combinations in patients (pts) with oestrogen receptor-positive (ER+), HER2-negative, locally advanced/metastatic BC (LA/mBC)
Presenter: Mafalda Oliveira
Session: Poster session 14
366P - Exploring the benefit of combining paclitaxel with capivasertib treatment in PI3K/AKT/PTEN-altered and non-altered TNBC preclinical models
Presenter: Cath Eberlein
Session: Poster session 14
367P - Phase I/II dose escalation study evaluating first-in-class eIF4A inhibitor zotatifin in ER+ metastatic breast cancer
Presenter: Ezra Rosen
Session: Poster session 14
368P - Tucidinostat and metronomic capecitabine plus endocrine therapy for patients with HR+/HER2- advanced breast cancer after CDK4/6 inhibitors: Preliminary findings of a multi-center, phase II study
Presenter: Qiufan Zheng
Session: Poster session 14
370P - A phase Ib study to evaluate the efficacy and safety of afuresertib plus fulvestrant in subjects with locally advanced or metastatic HR+/HER2- breast cancer who failed standard of care therapies: A subgroup analysis of efficacy in PIK3CA/AKT1/PTEN-altered subjects
Presenter: Pin Zhang
Session: Poster session 14
371P - Efficacy of metronomic capecitabine plus aromatase inhibitor as initial therapy in patients with hormone receptor-positive, HER2-negative metastatic breast cancer: The phase III MECCA trial
Presenter: Shusen Wang
Session: Poster session 14